AUG 12, 2026 · PHASE 2 TRIAL
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
ClinicalTrials.gov
This is a Phase 2 clinical trial registration with no reported results; the study is not yet recruiting and outcome data are not available in this registry record.
Reported
Planned sample size270
Study phasePhase 2
Primary outcome measureClinical Dementia Rating scale (CDR) sum of…